5 Key Takeaways
-
1
Next-generation biologics and gene therapies for neovascular age-related macular degeneration (nAMD) aim to enhance durability and reduce treatment burden.
-
2
Therapies like aflibercept 8 mg and faricimab are designed for longer dosing intervals, improving patient convenience.
-
3
Multitargeted therapies are being developed to address multiple pathways involved in nAMD, potentially improving treatment efficacy.
-
4
Investigational agents such as Tarcocimab tedromer and RC28-E are currently undergoing clinical trials to evaluate their safety and effectiveness.
-
5
Tyrosine kinase inhibitors like Axpaxli show promise in outperforming standard treatments, with ongoing trials supporting their potential use.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.